During this COCA Call, presenters will discuss the epidemiology of overdoses involving xylazine mixed with fentanyl, the current understanding of health risks related to these overdoses, and acute treatment strategies.
The non-opioid drug xylazine has been found in the U.S. illegal drug supply and is associated with overdose deaths from fentanyl. Xylazine is not approved for use in people and can cause sedation and other adverse health effects. Presenters will review the state of laboratory testing, outline potential harm reduction activities, and provide an example of an ongoing public health and clinical partnership to mitigate harms from xylazine mixed with fentanyl.
Thursday, February 29, 2024 | 1:00 – 2:00 pm CT
Registration is not required.
Webinar ID: 160 603 4857
Passcode: 432103
Telephone: +1-669-254-5252, or, +1-646-828-7666
Objectives:
- Cite background information on the topic covered during the presentation.
- Discuss CDC’s role in the topic covered during the presentation.
- Describe the topic’s implications for clinicians.
- Discuss concerns and/or issues related to preparedness for and/or response to urgent public health threats.
- Promote health improvement, wellness, and disease prevention in cooperation with patients, communities, at-risk populations, and other members of an interprofessional team of healthcare providers.
For more information for this event, visit the CDC COCA call webpage.
If you are unable to attend the live COCA Call, the recording will be available for viewing on the COCA Call webpage a few hours after the live event ends. The slide set will be available on the day of the call on the COCA Call webpage under Call Materials. Free Continuing Education (CE) will be offered for this COCA Call.